Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a competitive field. Hiroyuki Okuzawa is working to keep it that way.

Daiichi Sankyo will be solely responsible for manufacturing and supply. In August 2024, the global co-development and co-commercialization agreement was expanded to include gocatamig (MK-6070/DS3280), ...

Daiichi Sankyo will present new clinical research across its oncology portfolio with more than 20 abstracts in multiple cancers at the 2025 American Society of Clinical Oncology Scientific Program.

New Delhi: Malaysia's IHH Healthcare is seeking JPY 200 billion (Rs 11,800 crore) in damages from Japan's Daiichi Sankyo for blocking its bid for control of Indian hospital operator Fortis.

IHH Healthcare, supported by Mitsui, has increased its compensation claim against Daiichi Sankyo to $1.3 billion in the Tokyo District Court, related to the Fortis Healthcare acquisition.

IHH Healthcare’s indirect subsidiary Northern TK Venture Pte Ltd (NTK) has increased its damages claim against Japanese pharma company Daiichi Sankyo Co. about tenfold to ₹ 11,800 crore or $1. ...

The revised claim stems from NTK’s allegations that Daiichi Sankyo obstructed its 2018 open offer to acquire shares in India’s Fortis Healthcare and its subsidiary Fortis Malar Hospitals.

Daiichi Sankyo and MSD have announced the first subject dosing in the Phase III Ideate-Esophageal01 trial, assessing the safety and efficacy of ifinatamab deruxtecan (I-DXd) in individuals with ...

Daiichi Sankyo is a commercial-stage biopharmaceutical company that is in strong financial health. As of fiscal 2024, it had a debt/EBITDA ratio of 0.3 times and over JPY 700 billion in cash and ...

Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer. The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are ...

Daiichi Sankyo is a consistent sponsor of the event and even served as co-chair of the festival’s Centennial Celebration Host Committee for the 2012 100-year anniversary version.

Japanese drugmaker Daiichi Sankyo has been a sponsor of the National Cherry Blossom Festival in Washington, D.C. since 1909 — when the company’s first president, Dr. Jokichi Takamine, donated 3,000 ...